Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

PRESS timings for resolving 13 C4 -glutamate 1 H signal at 9.4 T: Demonstration in rat with uniformly labelled 13 C-glucose.

Dobberthien BJ, Tessier AG, Stanislaus AE, Sawyer MB, Fallone BG, Yahya A.

NMR Biomed. 2019 Sep 13:e4180. doi: 10.1002/nbm.4180. [Epub ahead of print]

PMID:
31518031
2.

Accuracy of Resting Energy Expenditure Predictive Equations in Patients With Cancer.

Purcell SA, Elliott SA, Baracos VE, Chu QSC, Sawyer MB, Mourtzakis M, Easaw JC, Spratlin JL, Siervo M, Prado CM.

Nutr Clin Pract. 2019 Jul 25. doi: 10.1002/ncp.10374. [Epub ahead of print]

PMID:
31347209
3.

Profiling Determinants of Resting Energy Expenditure in Colorectal Cancer.

Purcell SA, Baracos VE, Chu QSC, Sawyer MB, Severin D, Mourtzakis M, Lieffers JR, Prado CM.

Nutr Cancer. 2019 Jul 8:1-8. doi: 10.1080/01635581.2019.1635172. [Epub ahead of print]

PMID:
31282744
4.

Total energy expenditure in patients with colorectal cancer: associations with body composition, physical activity, and energy recommendations.

Purcell SA, Elliott SA, Walter PJ, Preston T, Cai H, Skipworth RJE, Sawyer MB, Prado CM.

Am J Clin Nutr. 2019 Aug 1;110(2):367-376. doi: 10.1093/ajcn/nqz112.

PMID:
31225583
5.

The Impact of Muscle and Adipose Tissue on Long-term Survival in Patients With Stage I to III Colorectal Cancer.

Hopkins JJ, Reif RL, Bigam DL, Baracos VE, Eurich DT, Sawyer MB.

Dis Colon Rectum. 2019 May;62(5):549-560. doi: 10.1097/DCR.0000000000001352.

PMID:
30789442
6.

Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.

Wong GG, Ha V, Chu MP, Dersch-Mills D, Ghosh S, Chambers CR, Sawyer MB.

Clin Colorectal Cancer. 2019 Mar;18(1):72-79. doi: 10.1016/j.clcc.2018.11.001. Epub 2018 Nov 16.

PMID:
30551953
7.

Poor Physical Function as a Marker of Sarcopenia in Adults with Class II/III Obesity.

Johnson Stoklossa CA, Ghosh SS, Forhan M, Sharma AM, Terada T, Siervo M, Baracos VE, Padwal RS, Hung PA, Sawyer MB, Maia YL, Prado CM.

Curr Dev Nutr. 2017 Dec 18;2(3):nzx008. doi: 10.3945/cdn.117.001743. eCollection 2018 Mar.

8.

Assessment of Computed Tomography (CT)-Defined Muscle and Adipose Tissue Features in Relation to Short-Term Outcomes After Elective Surgery for Colorectal Cancer: A Multicenter Approach.

Martin L, Hopkins J, Malietzis G, Jenkins JT, Sawyer MB, Brisebois R, MacLean A, Nelson G, Gramlich L, Baracos VE.

Ann Surg Oncol. 2018 Sep;25(9):2669-2680. doi: 10.1245/s10434-018-6652-x. Epub 2018 Jul 13.

PMID:
30006691
9.

Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes.

Damaraju VL, Kuzma M, Cass CE, Putman CT, Sawyer MB.

Biochem Pharmacol. 2018 Sep;155:162-171. doi: 10.1016/j.bcp.2018.07.001. Epub 2018 Jul 2.

PMID:
29983397
10.

Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments.

Hopkins JJ, Sawyer MB.

Cancer Chemother Pharmacol. 2018 Jul;82(1):1-29. doi: 10.1007/s00280-018-3614-8. Epub 2018 Jun 6. Review.

PMID:
29876640
11.

Accuracy of a Portable Indirect Calorimeter for Measuring Resting Energy Expenditure in Individuals With Cancer.

Purcell SA, Elliott SA, Ryan AM, Sawyer MB, Prado CM.

JPEN J Parenter Enteral Nutr. 2019 Jan;43(1):145-151. doi: 10.1002/jpen.1310. Epub 2018 Jun 5.

PMID:
29870086
12.

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.

Finn RS, Ahn DH, Javle MM, Tan BR Jr, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS.

Invest New Drugs. 2018 Dec;36(6):1037-1043. doi: 10.1007/s10637-018-0600-2. Epub 2018 May 22.

PMID:
29785570
13.

Barriers to the Interpretation of Body Composition in Colorectal Cancer: A Review of the Methodological Inconsistency and Complexity of the CT-Defined Body Habitus.

Hopkins JJ, Skubleny D, Bigam DL, Baracos VE, Eurich DT, Sawyer MB.

Ann Surg Oncol. 2018 May;25(5):1381-1394. doi: 10.1245/s10434-018-6395-8. Epub 2018 Feb 27. Review.

PMID:
29488190
14.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T.

J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

PMID:
29355075
15.

Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer-Reply.

Chu MP, Sawyer MB.

JAMA Oncol. 2018 Feb 1;4(2):265. doi: 10.1001/jamaoncol.2017.3410. No abstract available.

PMID:
29098275
16.

Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant.

Montano-Loza AJ, Mazurak VC, Ebadi M, Meza-Junco J, Sawyer MB, Baracos VE, Kneteman N.

Hepatology. 2018 Mar;67(3):914-923. doi: 10.1002/hep.29578. Epub 2018 Jan 26.

PMID:
29023899
17.

A review of body composition and pharmacokinetics in oncology.

Hopkins JJ, Sawyer MB.

Expert Rev Clin Pharmacol. 2017 Sep;10(9):947-956. doi: 10.1080/17512433.2017.1347503. Epub 2017 Jul 5. Review.

PMID:
28649898
18.

A Nutritional Perspective of Ketogenic Diet in Cancer: A Narrative Review.

Oliveira CLP, Mattingly S, Schirrmacher R, Sawyer MB, Fine EJ, Prado CM.

J Acad Nutr Diet. 2018 Apr;118(4):668-688. doi: 10.1016/j.jand.2017.02.003. Epub 2017 Mar 30.

PMID:
28366810
19.

Baxter elastomeric pumps: Weighing as an alternative to visual inspection.

Cusano EL, Ali R, Sawyer MB, Chambers CR, Tang PA.

J Oncol Pharm Pract. 2018 Apr;24(3):163-169. doi: 10.1177/1078155216687153. Epub 2017 Jan 11.

PMID:
28077048
20.

Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy.

Chu MP, Lieffers J, Ghosh S, Belch A, Chua NS, Fontaine A, Sangha R, Turner RA, Baracos VE, Sawyer MB.

J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):298-304. doi: 10.1002/jcsm.12161. Epub 2016 Nov 21.

21.

Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer.

Sjøblom B, Benth JŠ, Grønberg BH, Baracos VE, Sawyer MB, Fløtten Ø, Hjermstad MJ, Aass N, Jordhøy M.

Clin Lung Cancer. 2017 Mar;18(2):e129-e136. doi: 10.1016/j.cllc.2016.09.008. Epub 2016 Oct 5.

PMID:
27825639
22.

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.

Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, King K, Koski S, Mulder K, Hiller JP, Scarfe A, Spratlin J, Huang YJ, Khan-Wasti S, Chua N, Sawyer MB.

JAMA Oncol. 2017 Jun 1;3(6):767-773. doi: 10.1001/jamaoncol.2016.3358. Erratum in: JAMA Oncol. 2017 Dec 1;3(12):1742.

23.

Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis.

Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CM, Sawyer MB, Beaumont C, Esfandiari N, Ma M, Baracos VE.

J Cachexia Sarcopenia Muscle. 2016 May;7(2):126-35. doi: 10.1002/jcsm.12039. Epub 2015 Jun 9.

24.
25.

Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.

Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, Mollevi C, Senesse P.

Cancer Med. 2016 Apr;5(4):607-16. doi: 10.1002/cam4.621. Epub 2016 Jan 27.

26.

Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients.

Sun J, Ilich AI, Kim CA, Chu MP, Wong GG, Ghosh S, Danilak M, Mulder KE, Spratlin JL, Chambers CR, Sawyer MB.

Clin Colorectal Cancer. 2016 Sep;15(3):257-63. doi: 10.1016/j.clcc.2015.12.008. Epub 2015 Dec 28.

PMID:
26803708
27.

Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis.

Purcell SA, Elliott SA, Kroenke CH, Sawyer MB, Prado CM.

Curr Oncol Rep. 2016 Feb;18(2):8. doi: 10.1007/s11912-015-0488-3. Review.

PMID:
26769113
28.

(1)H-NMR urinary metabolomic profiling for diagnosis of gastric cancer.

Chan AW, Mercier P, Schiller D, Bailey R, Robbins S, Eurich DT, Sawyer MB, Broadhurst D.

Br J Cancer. 2016 Jan 12;114(1):59-62. doi: 10.1038/bjc.2015.414. Epub 2015 Dec 8.

29.

Cancer Cachexia: Emerging pre-clinical evidence and the pathway forward to clinical trials.

Martin L, Sawyer MB.

J Natl Cancer Inst. 2015 Oct 9;107(12):djv322. doi: 10.1093/jnci/djv322. Print 2015 Dec. No abstract available.

PMID:
26453482
30.

A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.

Sawyer MB, Pituskin E, Damaraju S, Bies RR, Vos LJ, Prado CM, Kuzma M, Scarfe AG, Clemons M, Tonkin K, Au HJ, Koski S, Joy AA, Smylie M, King K, Carandang D, Damaraju VL, Hanson J, Cass CE, Mackey JR.

Clin Breast Cancer. 2016 Apr;16(2):139-44.e1-3. doi: 10.1016/j.clbc.2015.09.006. Epub 2015 Sep 25.

PMID:
26452313
31.
32.
33.

Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors.

Damaraju VL, Kuzma M, Cass CE, Sawyer MB.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1093-8. doi: 10.1007/s00280-015-2859-8. Epub 2015 Sep 2.

PMID:
26330332
34.

Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis.

Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, Baracos VE, Sawyer MB, Pang JX, Beaumont C, Esfandiari N, Myers RP.

Clin Transl Gastroenterol. 2015 Jul 16;6:e102. doi: 10.1038/ctg.2015.31.

35.

Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy.

Chu MP, Lieffers J, Ghosh S, Belch AR, Chua NS, Fontaine A, Sangha R, Turner AR, Baracos VE, Sawyer MB.

PLoS One. 2015 Jun 1;10(6):e0127589. doi: 10.1371/journal.pone.0127589. eCollection 2015.

36.

Effects of gender on capecitabine toxicity in colorectal cancer.

Ilich AI, Danilak M, Kim CA, Mulder KE, Spratlin JL, Ghosh S, Chambers CR, Sawyer MB.

J Oncol Pharm Pract. 2016 Jun;22(3):454-60. doi: 10.1177/1078155215587345. Epub 2015 May 22.

PMID:
26002954
37.

Development of a new equation to estimate creatinine clearance in cancer patients.

Chu MP, McCaw L, Stretch C, Butts C, Hanson J, Kuzma M, Damaraju VL, Baracos VE, Sawyer MB.

Cancer Chemother Pharmacol. 2015 Jul;76(1):117-24. doi: 10.1007/s00280-015-2777-9. Epub 2015 May 19.

PMID:
25986679
38.

Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?

Damaraju VL, Kuzma M, Mowles D, Cass CE, Sawyer MB.

Mol Cancer Ther. 2015 Jan;14(1):236-45. doi: 10.1158/1535-7163.MCT-14-0337. Epub 2014 Dec 17.

39.

Carcinoma of unknown primary in the inguinal lymph node region of squamous cell origin: A case series.

Joseph K, Sawyer MB, Amanie J, Jones Thachuthara J, Ghosh S, Tai P.

Pract Radiat Oncol. 2014 Nov-Dec;4(6):404-8. doi: 10.1016/j.prro.2013.12.007. Epub 2014 Feb 18.

PMID:
25407862
40.

Potential role of metabolomics in diagnosis and surveillance of gastric cancer.

Chan AW, Gill RS, Schiller D, Sawyer MB.

World J Gastroenterol. 2014 Sep 28;20(36):12874-82. doi: 10.3748/wjg.v20.i36.12874. Review.

41.

Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.

Chu MP, Ghosh S, Chambers CR, Basappa N, Butts CA, Chu Q, Fenton D, Joy AA, Sangha R, Smylie M, Sawyer MB.

Clin Lung Cancer. 2015 Jan;16(1):33-9. doi: 10.1016/j.cllc.2014.07.005. Epub 2014 Aug 15.

PMID:
25246385
42.

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.

Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH Jr, Bagalà C, Colombi F, Cagnazzo C, Gioeni L, Wang E, Huang B, Fly KD, Leone F.

Ann Oncol. 2014 Sep;25(9):1750-5. doi: 10.1093/annonc/mdu205. Epub 2014 Jun 6.

43.

The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.

Prado CM, Baracos VE, Xiao J, Birdsell L, Stuyckens K, Park YC, Parekh T, Sawyer MB.

Appl Physiol Nutr Metab. 2014 Jun;39(6):693-8. doi: 10.1139/apnm-2013-0403. Epub 2014 Jan 23.

PMID:
24869973
44.

Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Kim CA, Price-Hiller J, Chu QS, Tankel K, Hennig R, Sawyer MB, Spratlin JL.

Invest New Drugs. 2014 Oct;32(5):1036-45. doi: 10.1007/s10637-014-0113-6. Epub 2014 May 23.

PMID:
24853074
45.

Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation.

Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, Beaumont C, Tandon P, Esfandiari N, Sawyer MB, Kneteman N.

Liver Transpl. 2014 Jun;20(6):640-8. doi: 10.1002/lt.23863. Epub 2014 Mar 26.

46.

Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?

Ha VH, Ngo M, Chu MP, Ghosh S, Sawyer MB, Chambers CR.

J Oncol Pharm Pract. 2015 Jun;21(3):194-200. doi: 10.1177/1078155214527145. Epub 2014 Mar 24.

PMID:
24664477
47.

The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats.

Lin XB, Farhangfar A, Valcheva R, Sawyer MB, Dieleman L, Schieber A, Gänzle MG, Baracos V.

PLoS One. 2014 Jan 14;9(1):e83644. doi: 10.1371/journal.pone.0083644. eCollection 2014.

48.

Liquid chromatography tandem mass spectrometry determination of free and conjugated estrogens in breast cancer patients before and after exemestane treatment.

Zhao Y, Boyd JM, Sawyer MB, Li XF.

Anal Chim Acta. 2014 Jan 2;806:172-9. doi: 10.1016/j.aca.2013.11.014. Epub 2013 Nov 16.

PMID:
24331053
49.

Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers.

Damaraju VL, Mowles D, Wilson M, Kuzma M, Cass CE, Sawyer MB.

Biochem Cell Biol. 2013 Dec;91(6):419-27. doi: 10.1139/bcb-2013-0041. Epub 2013 Jun 17.

PMID:
24219283
50.

Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.

Damaraju VL, Scriver T, Mowles D, Kuzma M, Ryan AJ, Cass CE, Sawyer MB.

Clin Cancer Res. 2014 Jan 1;20(1):176-86. doi: 10.1158/1078-0432.CCR-13-2293. Epub 2013 Oct 29.

Supplemental Content

Loading ...
Support Center